Switch theme
Sign up to access all valuation multiples
TaiMed Biologics Inc is a biotechnology company committed to have the expertise and capability in developing, manufacturing and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 (TMB-365 and TMB-380 combination), and Antibody-Drug Conjugates, ADCs.
2007
n/a
LTM Revenue $21.4M
LTM EBITDA -$2.7M
$667M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TaiMed Biologics has a last 12-month revenue (LTM) of $21.4M and a last 12-month EBITDA of -$2.7M.
In the most recent fiscal year, TaiMed Biologics achieved revenue of $20.4M and an EBITDA of -$1.2M.
TaiMed Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TaiMed Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.4M | XXX | $20.4M | XXX | XXX | XXX |
| Gross Profit | $7.9M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | -$2.7M | XXX | -$1.2M | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -6% | XXX | XXX | XXX |
| EBIT | -$8.0M | XXX | -$8.4M | XXX | XXX | XXX |
| EBIT Margin | -37% | XXX | -41% | XXX | XXX | XXX |
| Net Profit | -$6.4M | XXX | -$6.7M | XXX | XXX | XXX |
| Net Margin | -30% | XXX | -33% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TaiMed Biologics's stock price is TWD 78 (or $3).
TaiMed Biologics has current market cap of TWD 21.2B (or $706M), and EV of TWD 20.0B (or $667M).
See TaiMed Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $667M | $706M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TaiMed Biologics has market cap of $706M and EV of $667M.
TaiMed Biologics's trades at 32.8x EV/Revenue multiple, and -572.4x EV/EBITDA.
Equity research analysts estimate TaiMed Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TaiMed Biologics has a P/E ratio of -109.6x.
See valuation multiples for TaiMed Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $706M | XXX | $706M | XXX | XXX | XXX |
| EV (current) | $667M | XXX | $667M | XXX | XXX | XXX |
| EV/Revenue | 31.2x | XXX | 32.8x | XXX | XXX | XXX |
| EV/EBITDA | -250.7x | XXX | -572.4x | XXX | XXX | XXX |
| EV/EBIT | -83.7x | XXX | -79.3x | XXX | XXX | XXX |
| EV/Gross Profit | 84.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -109.6x | XXX | -104.9x | XXX | XXX | XXX |
| EV/FCF | -121.2x | XXX | -50.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTaiMed Biologics's last 12 month revenue growth is 7%
TaiMed Biologics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
TaiMed Biologics's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TaiMed Biologics's rule of X is 5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TaiMed Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TaiMed Biologics acquired XXX companies to date.
Last acquisition by TaiMed Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . TaiMed Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TaiMed Biologics founded? | TaiMed Biologics was founded in 2007. |
| Where is TaiMed Biologics headquartered? | TaiMed Biologics is headquartered in Taiwan. |
| Is TaiMed Biologics publicy listed? | Yes, TaiMed Biologics is a public company listed on ROCO. |
| What is the stock symbol of TaiMed Biologics? | TaiMed Biologics trades under 4147 ticker. |
| When did TaiMed Biologics go public? | TaiMed Biologics went public in 2010. |
| Who are competitors of TaiMed Biologics? | Similar companies to TaiMed Biologics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TaiMed Biologics? | TaiMed Biologics's current market cap is $706M |
| What is the current revenue of TaiMed Biologics? | TaiMed Biologics's last 12 months revenue is $21.4M. |
| What is the current revenue growth of TaiMed Biologics? | TaiMed Biologics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of TaiMed Biologics? | Current revenue multiple of TaiMed Biologics is 31.2x. |
| Is TaiMed Biologics profitable? | Yes, TaiMed Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TaiMed Biologics? | TaiMed Biologics's last 12 months EBITDA is -$2.7M. |
| What is TaiMed Biologics's EBITDA margin? | TaiMed Biologics's last 12 months EBITDA margin is -12%. |
| What is the current EV/EBITDA multiple of TaiMed Biologics? | Current EBITDA multiple of TaiMed Biologics is -250.7x. |
| What is the current FCF of TaiMed Biologics? | TaiMed Biologics's last 12 months FCF is -$5.5M. |
| What is TaiMed Biologics's FCF margin? | TaiMed Biologics's last 12 months FCF margin is -26%. |
| What is the current EV/FCF multiple of TaiMed Biologics? | Current FCF multiple of TaiMed Biologics is -121.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
